tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

AIM Stock Latest News

AIM reports preliminary data in Phase 1b/2 study of Ampligen, Imfinzi
The FlyAIM reports preliminary data in Phase 1b/2 study of Ampligen, Imfinzi
5m ago
AIM
AZN
AIM ImmunoTech Adjusts Executive Compensation and Agreements
PremiumCompany Announcements
AIM ImmunoTech Adjusts Executive Compensation and Agreements
7d ago
8K
AIM
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
PremiumPress Releases
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
8d ago
AIM
AIM ImmunoTech completed a clinical patient data analysis on AMP-518
PremiumThe Fly
AIM ImmunoTech completed a clinical patient data analysis on AMP-518
8d ago
AIM
AIM ImmunoTech announces official print of data analysis for EAP study of PDAC
PremiumThe Fly
AIM ImmunoTech announces official print of data analysis for EAP study of PDAC
30d ago
AIM
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
PremiumPress ReleasesAIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
30d ago
AIM
Morning Movers: MSG Entertainment rises following quarterly release
Premium
The Fly
Morning Movers: MSG Entertainment rises following quarterly release
1M ago
AIM
HRB
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Premium
Press Releases
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
1M ago
AIM
AIM ImmunoTech reports Q2 EPS (3c), consensus (12c)
PremiumThe Fly
AIM ImmunoTech reports Q2 EPS (3c), consensus (12c)
1M ago
AIM
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
PremiumPress Releases
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
1M ago
AIM
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
PremiumPress Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
2M ago
AIM
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
PremiumPress Releases
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
2M ago
AIM
AIM ImmunoTech announces data on Ampligen’s anti-tumor potential
PremiumThe FlyAIM ImmunoTech announces data on Ampligen’s anti-tumor potential
2M ago
AIM
AIM ImmunoTech files to sell 11.28M shares of common stock for holders
Premium
The Fly
AIM ImmunoTech files to sell 11.28M shares of common stock for holders
2M ago
AIM
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Premium
Press Releases
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
3M ago
AIM
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
PremiumPress Releases
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
3M ago
AIM
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
PremiumPress Releases
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
4M ago
AIM
AIM ImmunoTech to sell 5.6M shares at 36.3c in registered direct offering
PremiumThe Fly
AIM ImmunoTech to sell 5.6M shares at 36.3c in registered direct offering
4M ago
AIM
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
PremiumPress Releases
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
4M ago
AIM
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
PremiumPress ReleasesAIM ImmunoTech to Participate in Two Upcoming Investor Conferences
4M ago
AIM
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
Premium
Press Releases
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
4M ago
AIM
AIM ImmunoTech reports Q1 EPS (12c) vs (8c) last year
Premium
The Fly
AIM ImmunoTech reports Q1 EPS (12c) vs (8c) last year
4M ago
AIM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >